http://www.elsevier.nl/gej-ng/10/42/35/40/47/49/abstract.html
|
Full text PDF files should
be viewed and printed using Adobe® Acrobat® Reader
version 3.01 or higher (Download here).
Further details about PDF and Adobe® Acrobat® Reader
can be found on our "PDF
FAQ" page. Note: A new access control system has recently been introduced. You may
need to register (once) for access, even if this was not necessary before. Thank
you for your patience. |
Vaccine, Vol. 19 (31) (2001) pp. 4519 - 4525
© 2001 Elsevier Science Ltd. All rights reserved.
PII: S0264-410X(01)00188-8
a
Department of Microbiology and Institute of Medical Research, College of
Medicine, Pochon CHA University, Kyonggi-do 487-800, South Korea
b Department of Anatomy, College of Medicine, Pochon CHA University,
Kyonggi-do 487-800, South Korea
c Department of Microbiology and Institute of Biomedical Science,
College of Medicine, Hanyang University, Seoul, South Korea
d Department of Pharmacology, Korea Food and Drug Administration,
Seoul, South Korea
e College of Pharmacy, Seoul National University, Seoul, South Korea
Received 1 February 2001; received in
revised form 9 May 2001; accepted 9 May 2001
Nasal administration is emerging as a new route of DNA vaccine delivery. We aimed
to study the extent of absorption and biodistribution of intranasally
administered plasmid DNA. After intranasal administration, the level of plasmid
DNA in the serum peaked at 1.5 h. The ratio of the area under the concentration
(AUC) after intranasal administration of DNA over the AUC after intravenous
administration was 0.14. At 15 min post inoculation, the highest organ
distribution was observed in the liver and the cervical lymph nodes showed the
highest level among the lymph nodes. At 24 h a higher localization of plasmids
to the brain than to the lung and spleen was notable. A significant level of
mRNA expression was observed in the lymph nodes. These results suggest that
plasmid DNA can be substantially absorbed and distributed to the lymph nodes
after intranasal administration, partly explaining the systemic immunogenicity
of intranasally administered plasmid DNA vaccines.
Keywords: Plasmid DNA; Nasal absorption; Distribution
*Corresponding author. Tel.: +82-31-542-6671; fax:
+82-31-543-2818
[Full
text] (PDF 206.5 Kb)
© Copyright
2001, Elsevier Science, All rights reserved.
ALL
INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR
GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE
KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED
AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO
VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU
ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.